from the above three variant databases were included, after which the candidates were subjected to segregation analysis (figure e-1). Additionally, dbSNP build 138 (http://www.ncbi.nlm.nih.gov/SNP/) variants were excluded except those with clinical association in NCBI ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/).
After applying the filtering criteria, low quality variants were excluded based on IGV visualization of sequence reads. 10 The qualifying variants were subjected to segregation analysis by capillary sequencing.
Even though mtDNA is not included in the SureSelect exome capture kit, an average of 35.7× sequencing coverage in the mitochondrial genome was obtained, due to the abundance of mitochondrial DNA in the cells. We called mtDNA variants using samtools. 11 The MITOMAP database (www.mitomap.org) was used to identify known mtDNA mutations and polymorphisms.
Cell surface binding assay
COS7 cells were seeded onto poly-d-lysine 12-mm cover slips in a six-well cell culture plate (3 × 10 5 cells/well) and co-transfected with LGI1-FLAG and ADAM22.
At 24 h after transfection, cells were fixed with paraformaldehyde/120 mM sucrose/100 mM HEPES (pH 7.4) at room temperature for 10 min and blocked with PBS containing 10 mg/ml bovine serum albumin for 10 min on ice. The fixed cells were stained with anti-FLAG antibody, followed by Cy3-conjugated secondary antibody. Then, the cells were permeabilized with 0.1% Triton X-100 for 10 min, blocked with PBS containing 10 mg/ml BSA, and stained with anti-ADAM22 polyclonal antibody, followed by Alexa488-conjugated secondary antibody and staining with Hoechst dye (33342, Invitrogen). Fluorescent images were taken with a confocal laser microscopy system (Carl Zeiss LSM 510; Carl Zeiss). For double staining of Ser799IlefsTer96 mutant and an ER marker (anti-KDEL antibody), transfected COS7 cells were fixed, permeabilized and blocked as described above.
Then, cells were stained with anti-ADAM22 and anti-KDEL antibodies, followed by Alexa488-and Cy3-conjugated secondary antibodies, respectively.
Immunoprecipitation
The transfected HEK293T cells were washed with PBS and subsequently lysed with 1% Triton X-100 and 50 µg/ml PMSF], and eluted with buffer B containing 0.25 mg/ml FLAG peptide 12 . The immunoprecipitates were separated by SDS-PAGE and gels were subjected to Western blotting.
Exome sequencing metrics
Exome sequencing of the proband produced 4.4 Gb of sequence with a mean coverage of 84.68× in the target regions, of which 96.2% and 92.8% were captured with at least 5× and 10×, respectively.
Lack of biallelic mutations in ADAM22 in other datasets
To attempt to identify more patients with mutations in ADAM22, we utilized exome data from our 29 other in-house exomes from patients with severe epilepsy syndromes (unpublished data, Laari A., Muona, M. et al.). In addition, we accessed 178 exomes or whole genomes of epileptic encephalopathy cases generated in EuroEPINOMICS Rare Epilepsy Syndromes consortium and exomes from >1000 children included in the Deciphering Developmental Disorders project, 13 where 24%
of the cases present with seizures. However, we did not identify rare, biallelic mutations in ADAM22 in these data. The horizontal dashed line at the log 2 -transformed signal intensity value of 6
indicates the conservative threshold that was used by the authors to define an 'expressed' gene. 18 The graph was generated based on data released by the Human Brain Transcriptome project 18 using exon-level microarray data of the transcriptome 
